Industrial Chemistry
Open Access

Microbial Fuel Cells; Industrial effluents; Energy generation; Electrode materials; Scaling up; Wastewater treatment; Technological challenges

Introduction

Microbial Fuel Cells (MFCs) have garnered significant attention in recent years due to their dual capability of treating industrial effluents while generating renewable energy. This innovative technology harnesses the metabolic processes of microorganisms to convert organic matter directly into electricity, offering a sustainable alternative to traditional wastewater treatment methods [1,2]. Originally conceived as a bioelectrochemical system for energy production, MFCs have evolved through advancements in electrode materials, microbial engineering, and system design, enabling their application in diverse industrial settings. This article provides a comprehensive overview of the fundamental principles underlying MFC operation, recent technological progress, and the challenges associated with scaling up these systems for industrial applications. Furthermore, it explores the wide-ranging applications of MFCs in treating industrial effluents, highlighting their potential to mitigate environmental pollution and contribute to renewable energy production [3,4]. Despite these advancements, several obstacles such as electrode scalability, biofilm management, and long-term operational stability hinder widespread implementation of MFCs in industrial contexts. By examining the current state of MFC technology and discussing potential solutions to existing challenges, this review aims to underscore the transformative potential of MFCs in advancing sustainable industrial practices and meeting global energy and environmental sustainability goals [5,6]. Microbial Fuel Cells (MFCs) represent a promising technology at the intersection of environmental remediation and renewable energy generation. Originally conceptualized as a means to harness microbial activity to generate electricity from organic waste, MFCs have evolved significantly over the past few decades [7,8]. This article explores the fundamental principles of MFCs, recent technological advancements, their applications in treating industrial effluents, scaling up challenges, and the potential obstacles that need to be overcome for widespread adoption.

Fundamentals of microbial fuel cells

At its core, an MFC utilizes the metabolic activity of bacteria to convert organic matter directly into electrical energy. The process involves bacteria oxidizing organic substrates as part of their metabolic processes, transferring electrons to an anode surface. These electrons then flow through an external circuit to a cathode, where they combine with protons and an electron acceptor (often oxygen) to form water. This flow of electrons constitutes an electric current, which can be harnessed to power external devices [9].

Recent technological progress

Recent advancements in MFC technology have focused on improving efficiency, scalability, and reliability.

Electrode materials: Enhanced electrode materials, such as carbon nanotubes or graphene, have been employed to increase surface area and improve electron transfer efficiency.

Microbial consortia: Engineering microbial communities optimized for specific substrates or environmental conditions has improved overall MFC performance and stability.

Cathode optimization: Novel cathode materials and designs have facilitated faster oxygen reduction reactions, thereby enhancing overall electricity generation efficiency.

System integration: Innovations in system design and integration have led to more robust MFC systems capable of treating larger volumes of industrial effluents [10].

Applications in industrial effluent treatment

One of the most significant applications of MFCs lies in the treatment of industrial wastewater and effluents. Industries produce vast amounts of organic-rich wastewater containing pollutants that can be challenging to degrade using traditional methods. MFCs offer a sustainable alternative by simultaneously treating wastewater and generating electricity. Key benefits include

Bioremediation: MFCs promote the degradation of organic pollutants through microbial metabolism, reducing chemical oxygen demand (COD) and removing contaminants.

Energy recovery: Electricity generated from MFCs can be used to power onsite equipment or fed back into the grid, offsetting energy costs and reducing carbon footprints.

Cost efficiency: While initial setup costs can be significant, operational savings over time, coupled with potential revenue from electricity sales, make MFCs economically viable in the long run.

Scaling up challenges

Despite the promising developments, scaling up MFC technology for industrial applications presents several challenges

Electrode scaling: Maintaining efficient electron transfer over larger electrode surfaces without compromising performance remains a challenge.

Biofilm management: Controlling and optimizing the microbial biofilm on electrode surfaces to ensure stable and predictable performance.

Long-term stability: Ensuring MFCs operate reliably over extended periods without significant drop in performance or microbial activity.

Integration with Existing Infrastructure: Adapting MFC systems to fit within existing industrial wastewater treatment processes and infrastructure.

Conclusion

Microbial Fuel Cells (MFCs) represent a promising technology at the intersection of environmental remediation and renewable energy generation. Throughout this review, we have explored the fundamental principles of MFC operation, highlighted recent advancements in technology, discussed their applications in industrial effluent treatment, and identified key challenges associated with scaling up and widespread adoption. Advancements in electrode materials, microbial consortia engineering, and system integration have significantly improved MFC performance, making them increasingly viable for industrial applications. MFCs offer a dual benefit of treating organic-rich industrial effluents while generating electricity, thereby promoting sustainable practices and reducing environmental impact. Looking forward, the future of MFCs hinges on overcoming these obstacles to realize their full potential in industrial settings. Collaborative efforts between researchers, engineers, and industry stakeholders will be essential in advancing MFC technology, optimizing system performance, and integrating these systems into existing industrial infrastructure.

1. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN (2009) Hyperglycemic crises in adult patients with diabetes. J Nurs 32: 1335-1343.

Indexed at, Google Scholar, Crossref

2. Schroeder EB, Donahoo WT, Goodrich GK, Raebel MA (2018) Validation of an algorithm for identifying type 1 diabetes in adults based on electronic health record data. Pharmacoepidemiol Drug Saf 27: 1053-1059.

Indexed at, Google Scholar, Crossref

3. Puls HA, Haas NL, Franklin BJ, Theyyunni N, Harvey CE, et al. (2021) Euglycemic diabetic ketoacidosis associated with SGLT2i use: case series. Am J Emerg Med 44: 11-13.

Indexed at, Google Scholar, Crossref

4. Yoo MJ, Long B, Brady WJ, Holian A, Sudhir A, et al. (2021) Immune checkpoint inhibitors: an emergency medicine focused review. Am J Emerg Med 50: 335-344.

Indexed at, Google Scholar, Crossref

5. Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui L, et al. (2019) Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. BMC Endocr Disord 19: 144.

Indexed at, Google Scholar, Crossref

6. Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, et al. (2017) Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer 5: 40.

Indexed at, Google Scholar, Crossref

7. Kotwal A, Haddox C, Block M, Kudva YC (2019) Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ.

Indexed at, Google Scholar, Crossref

8. Nikouline A, Brzozowski M (2021) New DKA in a geriatric patient on immune checkpoint inhibitor therapy: a case report. CJEM 23: 712-714.

Indexed at, Google Scholar, Crossref

9. Maamari J, Yeung SCJ, Chaftari PS (2019) Diabetic ketoacidosis induced by a single dose of pembrolizumab. Pharmacoepidemiol Drug Saf 37: 376.

Indexed at, Google Scholar, Crossref

10. Mae S, Kuriyama A, Tachibana H (2021) Diabetic ketoacidosis as a delayed immune-related event after discontinuation of nivolumab. J Emerg Med 60: 342-344.

Indexed at, Google Scholar, Crossref